Dipeptidyl Peptidase-4 (DPP-4) Inhibitors prior authorization
Customize your policy alerts
Sign up for Delaware First Health Policy CP.PMN.03 alerts
Get alerted when Policy CP.PMN.03 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, coverage criteria, and continuation requirements for DPP-4 inhibitor medications for adults with type 2 diabetes mellitus under Delaware First Health (Medicaid). Applies to provider requests for listed DPP-4 products and certain combination products.
No material clinical or coverage changes in this revision.
Coverage Criteria — DPP-4 Inhibitors
Initial Therapy — Type 2 Diabetes Mellitus
Covered when ALL of the following are met:
Continued Therapy — Type 2 Diabetes Mellitus
Continued therapy covered when ALL of the following are met:
Other Diagnoses/Indications
Coverage approach — Guideline and formulary alignment
Coverage aligns with standard diabetes treatment escalation and formulary preferences.
Based on ADA and AACE/ACE guidance.
See review history for timing of additions and preference changes.
Requirement added in recent reviews.
DPP-4 inhibitors are not indicated for patients with type 1 diabetes and should not be used for that population. Onglyza (saxagliptin) and Kombiglyze (saxagliptin/metformin) are not to be used for the treatment of diabetic ketoacidosis (DKA). Additionally, several listed products (including Brynovin, Januvia, Janumet, Janumet XR, Jentadueto, Jentadueto XR, Tradjenta, Zituvimet, Zituvimet XR, and Zituvio) have not been studied in patients with a history of pancreatitis; prescribers should consider this when assessing risk. Uses that are not FDA-approved and are not addressed in this policy are not covered unless there is sufficient documentation of efficacy and safety consistent with the off‑label use policy (CP.PMN.53) or applicable evidence of coverage documents.
Concurrent prescribing of a DPP-4 inhibitor with a GLP‑1 receptor agonist is prohibited by the duplicate therapy restriction implemented in this policy. Requests for DPP-4 therapy that would result in overlapping treatment with a GLP‑1 agonist will be denied in accordance with the duplicate therapy edit.
Coverage is not authorized for indications that are not FDA‑approved and are not specifically addressed in this policy. Such off‑label requests must be supported by sufficient clinical documentation demonstrating efficacy and safety and must comply with the plan’s off‑label use policy (CP.PMN.53) or other applicable evidence‑of‑coverage provisions.
Key Clinical Thresholds and Coding Notes
Provider Requirements and Operational Notes
Prior authorization required
Prior authorization is required for the listed DPP‑4 inhibitor agents and their metformin combinations; requests for combination products that include an SGLT2 inhibitor should be referred to the SGLT2 Inhibitors policy (CP.PMN.14).
Formulary preference and redirection to generics
Policy revisions direct redirection to saxagliptin‑containing and sitagliptin‑containing products, indicating preference for generic saxagliptin and authorized‑generic sitagliptin/sitagliptin‑metformin where applicable; newly approved branded products (e.g., Zituvio, Zituvimet, Brynovin) were added to the criteria in recent reviews.
- Redirection to saxagliptin-containing products (generic preferred)
- Redirection to sitagliptin-containing products (authorized generics preferred)
- New branded products added to criteria in 2023–2025 reviews
Preferred generic requirement for brand requests
For most brand requests, the policy requires use of specified generic alternatives unless contraindicated or clinically significant adverse effects are present — e.g., generic saxagliptin (or generic saxagliptin/metformin) and sitagliptin (Zituvio authorized generic) or sitagliptin/metformin (Zituvimet authorized generic).
- Generic saxagliptin or saxagliptin/metformin preferred for Onglyza/Kombiglyze XR requests
- Authorized‑generic sitagliptin and sitagliptin/metformin preferred for Januvia/Janumet requests
Therapeutic escalation per ADA/AACE guidance
Follow guideline‑based escalation: metformin is recommended first‑line for type 2 diabetes; consider initiating dual therapy (metformin plus a DPP‑4 inhibitor) when baseline HbA1c is ≥1.5% above target; if monotherapy fails after ~3 months, add a second agent; if dual therapy is inadequate after ~3 months, initiate triple therapy; consider combination with insulin for baseline HbA1c >10% or symptomatic hyperglycemia.
- Metformin first-line for all patients per ADA/AACE/ACE
- Start dual therapy if baseline HbA1c ≥1.5% above target
- Escalate monotherapy → dual → triple, then consider insulin if needed
Required clinical documentation for authorization
Provider must submit office chart notes, laboratory results (for example, recent HbA1c) or other clinical information demonstrating the member meets the approval criteria.
- Include recent HbA1c results when relevant
- Submit documentation of prior trials of preferred generics or alternatives as required by step therapy
General documentation note — policy as a medical necessity guide
This clinical policy is a guide to medical necessity; providers should document clinical rationale consistent with standards of practice and benefit terms when submitting requests.
- Document rationale consistent with accepted clinical practice and benefit terms
- Include supporting evidence referenced in clinical notes or labs
Documentation required to demonstrate criteria are met
Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria when requesting prior authorization or continuation.
- Provide evidence of prior trials (≥3 months each) of required agents when applicable
- Provide documentation of clinical response for continuation requests
Duplicate therapy restriction — no concurrent GLP‑1 use
Concurrent prescribing of a DPP‑4 inhibitor with a GLP‑1 receptor agonist is restricted; requests must not be for concurrent use and duplicate therapy edits apply.
- Examples of GLP‑1 receptor agonists include liraglutide and dulaglutide (Trulicity)
- Concurrent use is prohibited per duplicate therapy edit added to the policy
Initial Therapy — Approval Conditions
Initial Therapy — Initial approval for type 2 diabetes mellitus requires all criteria below.
Initial approval for type 2 diabetes mellitus requires all criteria below.
Initial therapy per guidelines
Guideline-based initial therapy considerations.
Derived from ADA and AACE/ACE guidelines.
Continuation Therapy — Renewal Conditions
Continued Therapy — Continued therapy approval requires ongoing benefit/previous approval and clinical response.
Continued therapy approval requires ongoing benefit or previous approval and clinical response.
Continuation therapy notes — Annual reviews and history
Annual reviews noted minimal changes; continuation consistent with prior criteria and updated references.
See Reviews, Revisions, and Approvals for dates and specifics.
Step Therapy Requirements
| Step requirement | Details |
|---|---|
| Trial required | Failure of each of the following after ≥ 3 consecutive months unless contraindicated or clinically significant adverse effects: (i) an alogliptin‑containing product (e.g., Nesina, Kazano, Oseni); (ii) a saxagliptin‑containing product (generic saxagliptin and generic saxagliptin/metformin preferred); (iii) a sitagliptin‑containing product (Zituvio authorized generic and Zituvimet authorized generic preferred). Alternatively, request for Brynovin is acceptable if member is unable to swallow tablets. |
| Brand substitution requirement | If request is for brand Onglyza or Kombiglyze XR, member must use generic saxagliptin or saxagliptin/metformin unless contraindicated or adverse effects. If request is for brand Januvia/Zituvio or Janumet/Janumet XR/Zituvimet/Zituvimet XR, member must use sitagliptin (Zituvio authorized generic) or sitagliptin/metformin (Zituvimet authorized generic) unless contraindicated or adverse effects. |
| Therapy stage | Recommended action |
|---|---|
| Monotherapy | If target HbA1c not achieved after ~3 months of monotherapy, initiate dual therapy. |
| Dual therapy | If dual therapy inadequate after ~3 months, initiate triple therapy. |
| Triple therapy | If triple therapy fails to achieve goal, consider initiating combination therapy with insulin; note consider starting insulin-containing combination up front for baseline HbA1c >10% or symptomatic hyperglycemia. |
Background
DPP‑4 inhibitors are intended as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Clinical guidance referenced in this policy aligns with major society recommendations that metformin be used as first‑line therapy for most patients; a DPP‑4 inhibitor may be added as part of dual therapy when indicated (for example, when baseline HbA1c is substantially above target). Where applicable, the policy requires a documented trial of metformin (or an appropriate alternative) for ≥ 3 consecutive months unless contraindicated or not tolerated before initiating DPP‑4 therapy for failure of monotherapy, and recognizes guideline scenarios where initial combination therapy may be appropriate for markedly elevated HbA1c.
Definitions and Targets
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.